Navigation Links
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities
Date:8/4/2011

d the investigator-sponsored Phase 1 trial evaluating OGX-427 in patients with superficial bladder cancer. We expect results from both trials in 2012, unchanged from previous guidance.
  • We expect to initiate the randomized Phase 2 clinical trial of OGX-427 in approximately 180 patients with metastatic bladder cancer in the second half of 2011.

  • Financial Results

  • Revenue for the second quarter increased to $1.9 million compared with $1.7 million in 2010. Revenue for the six months ended June 30, 2011 decreased to $3.1 million from $6.4 million in 2010. Revenue is earned through reimbursements received under the Teva collaboration, as well as recognition of upfront payments we received from Teva.  
  • Revenue increased for the second quarter of 2011 due to increased efforts associated with the custirsen Phase 3 clinical trials.
  • Revenue decreased during the six months ended June 30, 2011 due to custirsen manufacturing activities now being paid directly by Teva.
  • As of June 30, 2011, $19.9 million of the $30.0 million upfront payment received from Teva in December 2009 was included in our Balance Sheet as Deferred Collaboration Revenue, which we are recognizing as we perform our deliverables under the agreement. We currently expect this performance period to end in the fourth quarter of 2013.
  • Total operating expenses for the second quarter increased to $6.9 million from $4.6 million in the second quarter of 2010.  Total operating expenses for the six months ended June 30, 2011 also increased to $13.3 million from $12.3 million during the same period in 2010.
  • The increase in operating expenses was primarily due to higher manufacturing and clinical trial costs for OGX-427, and higher employee expenses, offset by lower custirsen manufacturing costs that are now being paid directly by Teva.
  • Net loss for the second quarter of 2011 increased to $6.5 million, or $0.67 per diluted com
    '/>"/>

  • SOURCE OncoGenex Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011
    2. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
    3. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
    4. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
    5. Keryx Biopharmaceuticals, Inc. to Host Conference Call on Second Quarter 2011 Financial Results
    6. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
    7. Pacira Pharmaceuticals, Inc. Announces Timing for Second Quarter 2011 Financial Results Webcast and Conference Call
    8. Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities
    9. Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
    10. Gamma Pharmaceuticals, Inc. Holds Special Shareholders Meeting
    11. Sigma-Tau Pharmaceuticals, Inc. Announces Addition of VP of Finance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Jan. 15, 2014  A novel wearable injector slightly larger than ... for patients to self-inject prescription drugs in the large doses ... blood diseases, autoimmune deficiencies, and genetic disorders.  ... $220B by 2018, according to analysts.   Many of these drugs ...
    (Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
    (Date:1/14/2014)... Jan. 14, 2014 The Brandeis Medical Center, led by Dr. ... a premier and affordable laser tattoo removal experience with the advanced ... is in providing high quality cosmetic services with cutting edge medical ... " Southern California has seen a dramatic increase ...
    Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
    (Date:4/24/2014)... 2014 ,Take me out to the ballgame, doesn,t ... chips. The more likely culprits include French fries, soda ... for children who play youth baseball, eating unhealthy food ... problems, according to researchers at Wake Forest Baptist Medical ... of Childhood Obesity , found that high-calorie snacks ...
    (Date:4/24/2014)... long thought to be boring and irrelevant, could offer ... disease. , Researcher Dr Milena Furtado, and her team ... University, found the heart cell fibroblast is a close ... healthy beating heart. , In research published today in ... cardiac fibroblasts are unique cells due to their genetic ...
    (Date:4/24/2014)... CHAMPAIGN, Ill. It is better to give than to ... enjoy giving, a new study suggests. , The study found ... such as giving their money to family members, are less ... thrill from taking risks or keeping the money for themselves. ... of the National Academy of Sciences . , The study ...
    (Date:4/24/2014)... The National Science Foundation has awarded LSU ... for Undergraduates (REU) Site grant in the amount ... of undergraduates from diverse social and educational backgrounds, ... Orleans area. The project will provide students ... of 2014-16. It will be led by ...
    (Date:4/23/2014)... stool from healthy, unrelated donors was safe and ... caused by Clostridium difficile , according to ... Infectious Diseases and available online. Known as ... whether given via a colonoscope or a nasogastric ... this promising treatment more readily available to patients. ...
    Breaking Medicine News(10 mins):Health News:Take the bat, leave the candy 2Health News:Boring cells could hold the key to heart disease 2Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2
    ... 2008) The American Heart Associations Los Angeles Division ... of the paramedic model in use around the country ... Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). ... Heart Awards to Dr. Criley and William Koenig, Los ...
    ... April 3, 2008 TeamStaff, Inc.,(Nasdaq: TSTF ... services, today announced that it entered into a ... security agreement with Sovereign,Business Capital ("SBC", formerly Business ... the loan credit facility, SBC takes,assignment of TeamStaff,s ...
    ... WEST BEND, Wis., April 3, 2008 Mach ... that the,final tests prior to large scale manufacturing ... week., "A highly qualified scientist from BioQual ... facility completing a technology transfer and,memorializing the protocols ...
    ... Earns Vesicare Gold Standard Status Over, Sales-Leading Detrol LA/Detrusitol ... ... Decision Resources, WALTHAM, Mass., April 3, 2008 Decision Resources, ... healthcare issues, finds that a drug,s effect on the,reduction of urge ...
    ... gases, radiation and pesticides as probable causes , , THURSDAY, ... the risk of miscarriage, apparently the result of being ... line of work, a new study found. , Not ... the risks, but veterinary offices and labs need to ...
    ... -- China Medical,Technologies, Inc. (the "Company") (Nasdaq: ... company that develops, manufactures and markets advanced,in-vitro ... tumor,therapy systems, today announced the completion of ... (the "Kit"), a prostate cancer-specific,molecular diagnostic test ...
    Cached Medicine News:Health News:Pioneer of paramedic model to be honored 2Health News:Pioneer of paramedic model to be honored 3Health News:TeamStaff Announces Amended Revolving Credit Facility with Sovereign Business Capital 2Health News:TeamStaff Announces Amended Revolving Credit Facility with Sovereign Business Capital 3Health News:Mach One Corporation Announces Completion of Final Tests Prior to Full Scale Production 2Health News:Astellas/GlaxoSmithKline's Vesicare Has Advantages Over Pfizer's Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence 2Health News:Women Veterinarians Face Higher Miscarriage Risk 2Health News:Women Veterinarians Face Higher Miscarriage Risk 3Health News:China Medical Technologies Completed the Development of Prostate Cancer FISH Reagent 2
    Advanced ergonomic design allows greater comfort even after long hours of use. The focus knob and stage handle are located equidistant from the operator, permitting one-handed operation in a natural ...
    ... These revised charts incorporate the slight change ... the 10 Sloan letters derived from the ... eyes during the ETDRS study. The original ... examination of 234 eyes. In addition to ...
    ... to diagnose Stereo and Binocular vision in children ... glasses. The test can be used for testing ... and depth perception. The Stereo Cube tests for ... arc and is ideal for optometric examinations as ...
    ... "natural" Stereotest consists of three test plates(6mm, 3mm, ... in a range of 600 - 15 seconds. ... can only be detected if stereopsis is present. ... risk of the patient learning the correct answer. ...
    Medicine Products: